Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Ongoing TX45 APEX Phase 2 Clinical Trial Results Expected in 2026: The global, 24-week APEX Phase 2 clinical trial is a double-blind, randomized, placebo-controlled study designed to evaluate the ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

The identification of BRP, an anti-obesity peptide, showcases the transformative role of AI in drug discovery and its ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...